213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18–20 September 2015

Neuromuscular Disorders

Volumn 26, Issue 8, 2016, Pages 523-534

  Benveniste, Olivier ^g,h   Rider, Lisa G ⁱ   Aggarwal, R ^a   Allenbach, Y ^a   Benveniste, O ^a   De Bleecker, J L ^a   de Groot, I ^a   Devilliers, H ^a   Hilton Jones, D ^b   Hogrel, J Y ^a   Lundberg, I E ^a   Mammen, A L ^a   Oakley, ^c   Oddis, C ^a   Padberg, G ^d   Ponce, D ^e   Rose, M R ^f   Sanner, H ^a   Selva O'Callaghan, A ^a   de Visser, M ^a   Wells, A ^f   Werth, V P ^a   more..

^a Myositis Support Group Southampton ^*  (United States)

^b Oriel College Oxford   (United Kingdom)

^c Myositis Support Group Southampton   (United Kingdom)

^d Research Director ENMC   (United States)

^e vry   (France)

^f London   (United Kingdom)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h Groupe Hospitalier Pitié Salpêtrière   (France)

ⁱ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ACCELEROMETRY; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DERMATOMYOSITIS; DISEASE ACTIVITY; FORCED VITAL CAPACITY; HUMAN; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; NETHERLANDS; OUTCOME ASSESSMENT; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOLOGY; WORKSHOP; CLINICAL TRIAL (TOPIC);

CLINICAL TRIALS AS TOPIC; HUMANS; MYOSITIS; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84990929623     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2016.05.014     Document Type: Conference Paper

References (105)

1. [1] Allenbach, Y., Keraen, J., Bouvier, A.-M., et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain, 2016 pii: aww054; [Epub ahead of print].
2. [2] Hoogendijk, J.E., Amato, A.A., Lecky, B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14 (2004), 337–345.
3. [3] Amato, A.A., Griggs, R.C., Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 61 (2003), 288–289.
4. [4] Van der Meulen, M.F., Bronner, I.M., Hoogendijk, J.E., et al. Polymyositis: an overdiagnosed entity. Neurology 61 (2003), 316–321.
5. [5] Troyanov, Y., Targoff, I.N., Tremblay, J.L., Goulet, J.R., Raymond, Y., Senecal, J.L., Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84 (2005), 231–249.
6. [6] Benveniste, O., Stenzel, W., Hilton-Jones, D., Sandri, M., Boyer, O., van Engelen, B.G.M., Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol (Berl), 2015, 10.1007/s00401-015-1384-5.
7. [7] Chung, T., Christopher-Stine, L., Paik, J.J., Corse, A., Mammen, A.L., The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 52 (2015), 189–195, 10.1002/mus.24642.
8. [8] Betteridge, Z., McHugh, N., Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med, 2015, 10.1111/joim.12451.
9. [9] Tjärnlund, A., Bottai, M., Rider, L., et al. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Arthritis Rheum, 2012, S323–4.
10. [10] Lloyd, T.E., Mammen, A.L., Amato, A.A., Weiss, M.D., Needham, M., Greenberg, S.A., Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 83 (2014), 426–433, 10.1212/WNL.0000000000000642.
11. [11] Oddis, C.V., Rider, L.G., Reed, A.M., et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52 (2005), 2607–2615, 10.1002/art.21291.
12. [12] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf, 2009.
13. [13] Cano, S.J., Hobart, J.C., Watch out, watch out, the FDA are about. Dev Med Child Neurol 50 (2008), 408–409, 10.1111/j.1469-8749.2008.00408.x.
14. [14] Mendell, J.R., Csimma, C., McDonald, C.M., et al. Challenges in drug development for muscle disease: a stakeholders’ meeting. Muscle Nerve 35 (2007), 8–16, 10.1002/mus.20686.
15. [15] Christopher-Stine, L., Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Curr Opin Rheumatol 22 (2010), 623–626, 10.1097/BOR.0b013e32833f8f72.
16. [16] Isenberg, D.A., Allen, E., Farewell, V., et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43 (2004), 49–54, 10.1093/rheumatology/keg427.
17. [17] Miller, F.W., Rider, L.G., Chung, Y.L., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40 (2001), 1262–1273.
18. [18] Rider, L.G., Giannini, E.H., Brunner, H.I., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50 (2004), 2281–2290.
19. [19] Rider, L.G., Werth, V.P., Huber, A.M., et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 63:Suppl. 11 (2011), S118–57, 10.1002/acr.20532.
20. [20] Rider, L.G., Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28 (2002), 935–977.
21. [21] Rider, L.G., Giannini, E.H., Harris-Love, M., et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30 (2003), 603–617.
22. [22] Oddis, C.V., Reed, A.M., Aggarwal, R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65 (2013), 314–324, 10.1002/art.37754.
23. [23] Lay report: outcome measures and clinical trial readiness in idiopathic inflammatory myopathies. September 18–20, 2015, Heemskerk, The Netherlands http://www.enmc.org/publications/workshop-reports/outcome-measures-and-clinical-trial-readiness-idiopathic-inflammatory-myopathies-iim n.d.
24. [24] De Bleecker, J.L., Lundberg, I.E., de Visser, M., ENMC myositis muscle biopsy study group. 193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November-2 December 2012, Naarden, The Netherlands. Neuromuscul Disord 23 (2013), 945–951, 10.1016/j.nmd.2013.07.007.
25. [25] De Bleecker, J.L., De Paepe, B., Aronica, E., et al. 205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies Part II 28–30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 25 (2015), 268–272, 10.1016/j.nmd.2014.12.001.
26. [26] Aouizerate, J., De Antonio, M., Bassez, G., et al. Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun, 2, 2014, 154, 10.1186/s40478-014-0154-2.
27. [27] Mescam-Mancini, L., Allenbach, Y., Hervier, B., et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138 (2015), 2485–2492, 10.1093/brain/awv192.
28. [28] Stenzel, W., Preuße, C., Allenbach, Y., et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 84:13 (2015), 1346–1354, 10.1212/WNL.0000000000001422.
29. [29] Allenbach, Y., Leroux, G., Calvet, X.S., et al. Dermatomyositis with or without anti-melanoma differentiation-associated protein 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 186:3 (2016), 691–700, 10.1016/j.ajpath.2015.11.010.
30. [30] Pinal-Fernandez, I., Casciola-Rosen, L.A., Christopher-Stine, L., Corse, A.M., Mammen, A.L., The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42 (2015), 1448–1454.
31. [31] Christopher-Stine, L., Casciola-Rosen, L.A., Hong, G., Chung, T., Corse, A.M., Mammen, A.L., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62 (2010), 2757–2766, 10.1002/art.27572.
32. [32] Love, L.A., Leff, R.L., Fraser, D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70 (1991), 360–374.
33. [33] Rider, L.G., Miller, F.W., Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305 (2011), 183–190, 10.1001/jama.2010.1977.
34. [34] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975), 403–407, 10.1056/NEJM197502202920807.
35. [35] Greenberg, S.A., Pinkus, J.L., Pinkus, G.S., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57 (2005), 664–678.
36. [36] Suárez-Calvet, X., Gallardo, E., Nogales-Gadea, G., et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol 233 (2014), 258–268, 10.1002/path.4346.
37. [37] Moghadam-Kia, S., Oddis, C.V., Sato, S., Kuwana, M., Aggarwal, R., Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res, 2015, 10.1002/acr.22728.
38. [38] Trallero-Araguás, E., Rodrigo-Pendás, J.Á., Selva-O'Callaghan, A., et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64 (2012), 523–532, 10.1002/art.33379.
39. [39] Hamaguchi, Y., Kuwana, M., Hoshino, K., et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147 (2011), 391–398, 10.1001/archdermatol.2011.52.
40. [40] Ruperto, N., Pistorio, A., Oliveira, S., et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387 (2016), 671–678, 10.1016/S0140-6736(15)01021-1.
41. [41] Devilliers, H., Shewaro, N., Allenbach, Y., Rigolet, A., Benveniste, O., P.21.9 Responsiveness of muscle testing and functions in a retrospective 51 inflammatory myopathies patient series. Neuromuscul Disord, 23, 2013, 846, 10.1016/j.nmd.2013.06.714.
42. [42] Vanhoutte, E.K., Faber, C.G., van Nes, S.I., et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 135 (2012), 1639–1649, 10.1093/brain/awr318.
43. [43] Seferian, A.M., Moraux, A., Annoussamy, M., et al. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial. PLoS ONE, 10, 2015, 10.1371/journal.pone.0113999 e0113999.
44. [44] Seferian, A.M., Moraux, A., Canal, A., et al. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS ONE, 10, 2015, 10.1371/journal.pone.0121799 e0121799.
45. [45] Allenbach, Y., Benveniste, O., Decostre, V., et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord 22 (2012), 980–986, 10.1016/j.nmd.2012.05.004.
46. [46] Hogrel, J.-Y., Allenbach, Y., Canal, A., et al. Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials. Neuromuscul Disord 24 (2014), 604–610, 10.1016/j.nmd.2014.04.009.
47. [47] Benveniste, O., Guiguet, M., Freebody, J., et al. Long-term observational study of sporadic inclusion body myositis. Brain 134 (2011), 3176–3184, 10.1093/brain/awr213.
48. [48] Jackson, C.E., Barohn, R.J., Gronseth, G., Pandya, S., Herbelin, L., Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 37 (2008), 473–476, 10.1002/mus.20958.
49. [49] Allenbach, Y., Foucher, A., Champtiaux, N., et al. Wrist-worn accelerometer as innovative tool for longitudinal follow-up of idiopathic inflammatory myopathy patients: a pilot study. Neuromuscul Disord, 25, 2015, S310, 10.1016/j.nmd.2015.06.442.
50. [50] IMACS website. http://www.niehs.nih.gov/research/resources/imacs/diseaseactivity/index.cfm n.d.
51. [51] Rider, L.G., Koziol, D., Giannini, E.H., et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62 (2010), 465–472, 10.1002/acr.20035.
52. [52] Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70 (2011), 427–436, 10.1002/ana.22477.
53. [53] Rider, L.G., Yip, A.L., Horkayne-Szakaly, I., et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol 32 (2014), 689–696.
54. [54] Alexanderson, H., Lundberg, I.E., Stenström, C.H., Development of the myositis activities profile – validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 29 (2002), 2386–2392.
55. [55] Ponyi, A., Borgulya, G., Constantin, T., Váncsa, A., Gergely, L., Dankó, K., Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 44 (2005), 83–88, 10.1093/rheumatology/keh404.
56. [56] Huber, A.M., Feldman, B.M., Rennebohm, R.M., et al. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 50 (2004), 1595–1603, 10.1002/art.20179.
57. [57] Ruperto, N., Ravelli, A., Pistorio, A., et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59 (2008), 4–13, 10.1002/art.23248.
58. [58] Alexanderson, H., Broman, L., Tollbäck, A., Josefson, A., Lundberg, I.E., Stenström, C.H., Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 55 (2006), 114–122, 10.1002/art.21715.
59. [59] Ernste, F., Alexanderson, H., Ytterberg, S., Reed, A., Validation of the Functional Index 3 in polymyositis and dermatomyositis. Arthritis Rheumatol Suppl, 2012, S324.
60. [60] Seedat, F., James, M.K., Rose, M.R., Activity rating scales in adult muscle disease: what do they actually measure?. Muscle Nerve 50 (2014), 14–23, 10.1002/mus.24093.
61. [61] Seedat, F., James, M.K., Rose, M.R., Activity rating scales in adult muscle disease: how well do they actually measure?. Muscle Nerve 50 (2014), 24–33, 10.1002/mus.24090.
62. [62] Aggarwal, R., Rider, L., Ruperto, N., et al. A consensus hybrid definition using a conjoint analysis is the proposed as response criteria for minimal and moderate improvement for adult polymyositis and dermatomyositis clinical trials. Arthritis Rheumatol Suppl, 2014, S404.
63. [63] Rider, L., Aggarwal, R., Bayat, N., et al. A hybrid conjoint analysis model is proposed as the definition of minimal, moderate and major clinical improvement in juvenile dermatomyositis clinical trials. Arthritis Rheumatol Suppl, 2014, S578.
64. [64] Sadjadi, R., Vincent, K.A., Carr, A.J., et al. Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK. Health Qual Life Outcomes, 9, 2011, 114, 10.1186/1477-7525-9-114.
65. [65] Sansone, V.A., Panzeri, M., Montanari, M., et al. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol 17 (2010), 1178–1187, 10.1111/j.1468-1331.2010.02992.x.
66. [66] Stone, K.B., Oddis, C.V., Fertig, N., et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56 (2007), 3125–3131, 10.1002/art.22865.
67. [67] Sultan, S.M., Allen, E., Oddis, C.V., et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 58 (2008), 3593–3599, 10.1002/art.23963.
68. [68] Saketkoo, L.A., Mittoo, S., Huscher, D., et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 69 (2014), 436–444, 10.1136/thoraxjnl-2013-204202.
69. [69] Klein, R.Q., Bangert, C.A., Costner, M., et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 159 (2008), 887–894, 10.1111/j.1365-2133.2008.08711.x.
70. [70] Anyanwu, C.O., Fiorentino, D.F., Chung, L., et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 173 (2015), 969–974, 10.1111/bjd.13915.
71. [71] Robinson, E.S., Feng, R., Okawa, J., Werth, V.P., Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br J Dermatol, 2014, 10.1111/bjd.13167.
72. [72] Goreshi, R., Chock, M., Foering, K., et al. Quality of life in dermatomyositis. J Am Acad Dermatol 65 (2011), 1107–1116, 10.1016/j.jaad.2010.10.016.
73. [73] Regardt, M., Basharat, P., Christopher-Stine, L., et al. Patients’ experience of myositis and further validation of a myositis-specific patient reported outcome measure – establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12. J Rheumatol 42 (2015), 2492–2495, 10.3899/jrheum.141243.
74. [74] Armadans-Tremolosa, I., Selva-O'Callaghan, A., Visauta-Vinacua, B., Guilera, G., Pinal-Fernández, I., Vilardell-Tarrés, M., Health-related quality of life and well-being in adults with idiopathic inflammatory myopathy. Clin Rheumatol 33 (2014), 1119–1125, 10.1007/s10067-014-2685-0.
75. [75] Rider, L.G., Lachenbruch, P.A., Monroe, J.B., et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60 (2009), 3425–3435, 10.1002/art.24904.
76. [76] Sultan, S.M., Allen, E., Cooper, R.G., et al. Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis 70 (2011), 1272–1276, 10.1136/ard.2010.142117.
77. [77] King, T.E., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092, 10.1056/NEJMoa1402582.
78. [78] Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082, 10.1056/NEJMoa1402584.
79. [79] Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007), 1026–1034, 10.1164/rccm.200702-326OC.
80. [80] Goh, N.S.L., Desai, S.R., Veeraraghavan, S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177 (2008), 1248–1254, 10.1164/rccm.200706-877OC.
81. [81] Khanna, D., Brown, K.K., Clements, P.J., et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 28 (2010), S55–62.
82. [82] Zappala, C.J., Latsi, P.I., Nicholson, A.G., et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35 (2010), 830–836, 10.1183/09031936.00155108.
83. [83] Goreshi, R., Okawa, J., Rose, M., et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 132 (2012), 1117–1124, 10.1038/jid.2011.440.
84. [84] Huber, A.M., Lachenbruch, P.A., Dugan, E.M., Miller, F.W., Rider, L.G., Juvenile dermatomyositis disease activity collaborative study group. Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum 59 (2008), 352–356, 10.1002/art.23313.
85. [85] Huber, A.M., Dugan, E.M., Lachenbruch, P.A., et al. Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis Rheum 59 (2008), 214–221, 10.1002/art.23340.
86. [86] Rider, L.G., Shah, M., Mamyrova, G., et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92 (2013), 223–243, 10.1097/MD.0b013e31829d08f9.
87. [87] Tansley, S.L., McHugh, N.J., Wedderburn, L.R., Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther, 15, 2013, 211, 10.1186/ar4198.
88. [88] Sanner, H., Gran, J.-T., Sjaastad, I., Flatø, B., Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48 (2009), 1541–1547, 10.1093/rheumatology/kep302.
89. [89] Sanner, H., Sjaastad, I., Flatø, B., Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 53 (2014), 1578–1585, 10.1093/rheumatology/keu146.
90. [90] Tollisen, A., Sanner, H., Flatø, B., Wahl, A.K., Quality of life in adults with juvenile-onset dermatomyositis: a case-control study. Arthritis Care Res 64 (2012), 1020–1027, 10.1002/acr.21637.
91. [91] Sanner, H., Kirkhus, E., Merckoll, E., et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study. Arthritis Care Res 62 (2010), 1103–1111, 10.1002/acr.20203.
92. [92] Sanner, H., Aaløkken, T.M., Gran, J.T., Sjaastad, I., Johansen, B., Flatø, B., Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70 (2011), 86–91, 10.1136/ard.2010.131433.
93. [93] Schwartz, T., Sanner, H., Husebye, T., Flatø, B., Sjaastad, I., Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70 (2011), 766–771, 10.1136/ard.2010.137968.
94. [94] Schwartz, T., Sanner, H., Gjesdal, O., Flatø, B., Sjaastad, I., In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis 73 (2014), 1805–1810, 10.1136/annrheumdis-2013-203279.
95. [95] Bronner, I.M., van der Meulen, M.F.G., de Visser, M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65 (2006), 1456–1461, 10.1136/ard.2005.045690.
96. [96] Chung, Y.L., Mitchell, H.L., Houssien, D.A., Al-Mahrouki, H., Carr, A.J., Scott, D.L., A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham health profile. Clin Exp Rheumatol 19 (2001), 447–450.
97. [97] Regardt, M., Welin Henriksson, E., Alexanderson, H., Lundberg, I.E., Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology (Oxford) 50 (2011), 578–585, 10.1093/rheumatology/keq356.
98. [98] Sultan, S.M., Ioannou, Y., Moss, K., Isenberg, D.A., Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41 (2002), 22–26.
99. [99] Busija, L., Pausenberger, E., Haines, T.P., Haymes, S., Buchbinder, R., Osborne, R.H., Adult measures of general health and health-related quality of life: medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res 63:Suppl. 11 (2011), S383–412, 10.1002/acr.20541.
100. [100] Vincent, K.A., Carr, A.J., Walburn, J., Scott, D.L., Rose, M.R., Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 68 (2007), 1051–1057, 10.1212/01.wnl.0000257819.47628.41.
101. [101] Peric, S., Sreckov, M., Basta, I., et al. Dependent and paranoid personality patterns in myotonic dystrophy type 1. Acta Neurol Scand 129 (2014), 219–225, 10.1111/ane.12173.
102. [102] Seesing, F.M., van Vught, L.E., Rose, M.R., Drost, G., van Engelen, B.G.M., van der Wilt, G.-J., The individualized neuromuscular quality of life questionnaire: cultural translation and psychometric validation for the Dutch population. Muscle Nerve 51 (2015), 496–500, 10.1002/mus.24337.
103. [103] Van de Vlekkert, J., Hoogendijk, J.E., de Visser, M., Long-term follow-up of 62 patients with myositis. J Neurol 261 (2014), 992–998, 10.1007/s00415-014-7313-z.
104. [104] Alemo Munters, L., Dastmalchi, M., Andgren, V., et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res 65 (2013), 1959–1968, 10.1002/acr.22068.
105. [105] Alexanderson, H., Del Grande, M., Bingham, C.O., et al. Patient-reported outcomes and adult patients’ disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 myositis special interest group. J Rheumatol 41 (2014), 581–592, 10.3899/jrheum.131247.